Epilepsy patients get continued access to brivaracetam through compassionate program
NCT ID NCT03532516
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This program provides brivaracetam (Briviact) to epilepsy patients who were already taking it in earlier studies, bridging the gap until the drug is commercially available. Patients continue their individual doses, up to 200 mg per day, with adjustments based on seizure control and side effects. Only patients who have already shown benefit and whose doctors agree that other treatments may not be suitable are eligible.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Brivaracetam (Briviact)
What this could lead to
If successful, this program could provide continuous seizure control for epilepsy patients who have already benefited from brivaracetam in prior studies.
What could go wrong
This is a compassionate use program, not a formal trial, so results are not systematically collected. It only includes patients already on the drug, so benefits may not apply to others.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPILEPSY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.